melperone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tranquillizers, neuroleptics, 4'-fluoro-4-piperidinobutyrophenone derivatives 1677 3575-80-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • melperone
  • flubuperone
  • methylperone
  • Molecular weight: 263.36
  • Formula: C16H22FNO
  • CLOGP: 3.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 20.31
  • ALOGS: -3.73
  • ROTB: 5

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.70 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 14 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 46 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1972 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Systemic infection 85.93 44.18 18 1235 2265 50601606
Sleep-related eating disorder 78.52 44.18 14 1239 754 50603117
Peripheral circulatory failure 62.46 44.18 11 1242 551 50603320
Syncope 51.84 44.18 32 1221 102970 50500901
General physical health deterioration 51.59 44.18 36 1217 142398 50461473
Epilepsy 45.98 44.18 18 1235 21549 50582322
Haematemesis 44.91 44.18 19 1234 27706 50576165

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 94.50 45.73 67 1072 177111 29396277
General physical health deterioration 66.61 45.73 44 1095 102813 29470575
Pleurothotonus 56.56 45.73 12 1127 1026 29572362
Disorientation 53.66 45.73 25 1114 29490 29543898
Gastrointestinal hypermotility 51.11 45.73 8 1131 121 29573267
Electrocardiogram QT shortened 49.95 45.73 8 1131 141 29573247
Fracture 47.79 45.73 15 1124 6038 29567350
Epilepsy 47.64 45.73 20 1119 18412 29554976

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 118.87 39.20 79 2184 204346 64292123
Fall 110.48 39.20 101 2162 416725 64079744
Pleurothotonus 79.47 39.20 18 2245 2284 64494185
Systemic infection 68.21 39.20 18 2245 4303 64492166
Disorientation 56.76 39.20 31 2232 55797 64440672
Sleep-related eating disorder 56.49 39.20 11 2252 671 64495798
Peripheral circulatory failure 56.34 39.20 11 2252 680 64495789
Epilepsy 55.80 39.20 26 2237 33505 64462964
Drug interaction 51.15 39.20 63 2200 362020 64134449
Depressed level of consciousness 43.56 39.20 30 2233 81406 64415063
Syncope 41.00 39.20 38 2225 157597 64338872

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AD03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Butyrophenone derivatives

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR Ki 6.98 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.82 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 5.66 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 6.72 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 5.68 PDSP
Alpha-1A adrenergic receptor GPCR Ki 6.74 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 7.06 WOMBAT-PK
Histamine H1 receptor GPCR Ki 6.24 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 5.62 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.36 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.47 PDSP
Cytochrome P450 2D6 Enzyme WOMBAT-PK
D(4) dopamine receptor GPCR Ki 6.39 WOMBAT-PK

External reference:

IDSource
D07309 KEGG_DRUG
C0066477 UMLSCUI
CHEBI:93626 CHEBI
CHEMBL1531134 ChEMBL_ID
DB09224 DRUGBANK_ID
15387 PUBCHEM_CID
2070 INN_ID
J8WA3K39B7 UNII
29961 RXNORM
006742 NDDF
441821005 SNOMEDCT_US
442519006 SNOMEDCT_US

Pharmaceutical products:

None